Back to results
US 2025/0144099 A1Published application
Ink4 tumor suppressor proteins mediate resistance to cdk4/6 kinase inhibitors
OwnerSarat Chandarlapaty, Qing Li +4inventors
InventorsSarat Chandarlapaty, Qing Li, Nathanael Gray, Baishan Jiang, Abhishek Sharma, Aiswarya Mini
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to compounds according to Formula (I), Formula (I) or a pharmaceutically acceptable salt and/or solvate thereof, compositions including such compounds, and methods useful for treating, preventing, and/or ameliorating a CDK4 and/or CDK6-mediated disorder, disease, or condition (e.g., cancer such as breast cancer) in a subject.
Claims22
A compound according to Formula (I)
- or a pharmaceutically acceptable salt and/or solvate thereof, wherein
- L is selected from the group consisting of
- T is selected from the group consisting of
- ring A is a 4- to 7-membered N-containing heterocycloalkylene optionally substituted with one or more groups selected from halogen and C1-C3 alkyl;
- Cy is a C4-C6 cycloalkylene optionally substituted with one or more groups selected from halogen and C1-C3 alkyl;
- R and R3 are each independently H or C1-C3 alkyl;
- R1 and R2 are taken together to form an oxo (=O) group;
- R4 is H, halo, C1-C4 alkyl, or C3-C6 cycloalkyl;
- L1 is a C1-C6 alkylene;
- * is the linkage site to the nitrogen atom of the piperazine moiety;
- and
- # is the linkage site to the T group.
9 more elements
(canceled)
-22. (canceled)
Dependencies are inferred from the claim text.